Critical Illness, Immunosuppression, Lymphopenia, Sepsis, Septic Shock
Conditions
Keywords
Sepsis, Septic shock, Persistent lymphopenia, Immunosuppression, IL-15 receptor agonist, Nogapendekin alfa inbakicept, N-803, ANKTIVA, Immune reconstitution, Critical care, ICU
Brief summary
This is a Phase 2, randomized, open-label study evaluating the safety and efficacy of nogapendekin alfa inbakicept (NAI, ANKTIVA®) in combination with standard of care versus standard of care alone in critically ill adults with sepsis and persistent lymphopenia. The study aims to determine whether NAI can improve 28-day mortality by addressing the immunosuppressive phase of sepsis characterized by persistent lymphopenia (absolute lymphocyte count \<1,000 cells/µL). Participants will be randomized 1:1 to receive either NAI 1.2 mg subcutaneous injection on Days 3 (or earlier if ALC \<700 cells/µL), Day 14, and potentially Day 21 if ALC remains \<1,000 cells/µL, plus standard of care, or standard of care alone. The study will enroll approximately 50 participants (25 per arm) with persistent lymphopenia.
Detailed description
Sepsis is characterized by a biphasic immune response: an initial hyperinflammatory phase followed by a prolonged immunosuppressive phase with persistent lymphopenia. The majority of sepsis deaths (\>70%) occur during the immunosuppressive phase rather than the initial hyperinflammatory phase. This acquired immunosuppression correlates with markedly increased 28-day mortality rates exceeding 40% and significantly elevated risk of secondary infections. This study evaluates NAI, an IL-15 receptor agonist that promotes proliferation and activation of NK cells and CD8+ T cells, as a potential therapy to restore immune function in critically ill adults with sepsis and persistent lymphopenia (ALC \<1,000 cells/µL on two consecutive measurements within 72 hours of sepsis diagnosis). Study Arms: * Experimental Arm: NAI 1.2 mg subcutaneous injection administered on Days 3 (or earlier than Day 3 if ALC is \<700 cells/µL), Day 14, and Day 21 if needed for ALC \<1,000 cells/µL, plus institutional standard of care for sepsis * Control Arm: Institutional standard of care for sepsis alone Standard of care may include antimicrobial therapy, fluid resuscitation, vasopressor support, organ support, and mechanical ventilation as clinically indicated. Treatment will be discontinued if a participant has unacceptable toxicity, withdraws consent, or if the Investigator feels it is no longer in the participant's best interest to continue. All participants will be followed for 90 days post the first dose of study treatment to capture late adverse events, rehospitalization, or mortality.
Interventions
IL-15 receptor agonist complex; 1.2 mg subcutaneous injection administered on Days 3 (or earlier if ALC \<700 cells/µL), Day 14, and Day 21 if needed for ALC \<1,000 cells/µL
OTHERStandard of Care (SOC)
Institutional standard of care for sepsis including antimicrobial therapy, fluid resuscitation, vasopressor support, organ support, and mechanical ventilation as clinically indicated
Sponsors
ImmunityBio, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age 18 years or older at the time of informed consent 2. Admitted to the ICU with a diagnosis of sepsis as defined by Sepsis-3 criteria: life-threatening organ dysfunction caused by a dysregulated host response to infection, operationalized as a Sequential Organ Failure Assessment (SOFA) score increase of 2 or more points 3. Documented persistent lymphopenia defined as ALC \<1,000 cells/µL on at least two consecutive measurements within 72 hours of sepsis diagnosis (measurements must be separated by at least 12 hours) 4. Prior initiation of appropriate antimicrobial therapy per institutional guidelines 5. Ability to obtain written informed consent from the participant or legally authorized representative 6. Agreement to practice effective contraception for female participants of child-bearing potential and non-sterile males (for up to 7 months after completion of therapy)
Exclusion criteria
1. Hematologic malignancies including leukemia, lymphoma, and myelodysplastic syndromes 2. Prior CAR-T cell therapy or hematopoietic stem cell transplant (HSCT) within 3 months of screening 3. Active cytokine release syndrome (CRS) at screening 4. Current or recent (within 7 days) use of colony stimulating factors (G-CSF, GM-CSF) 5. Lymphopenia attributable to chemotherapy, radiation therapy, or immunosuppressive medications administered within 30 days prior to screening 6. High-dose immunosuppressive therapy (\>0.5 mg/kg prednisone equivalent daily), excluding physiologic replacement and stress-dose hydrocortisone for septic shock 7. Life expectancy less than 24 hours as assessed by the treating physician 8. Active uncontrolled bleeding requiring \>2 units of packed red blood cells in the preceding 24 hours 9. Known HIV infection with CD4 count \<350 cells/µL and detectable viral load 10. Known active viral hepatitis (hepatitis B or C with detectable viral load) 11. Advanced dementia or other conditions precluding meaningful participation 12. Known hypersensitivity to any component of the investigational products 13. Participation in another interventional trial with an investigational immunomodulatory agent within 30 days prior to screening 14. Pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 28-day all-cause mortality rate | 28 days | Proportion of participants who die from any cause within 28 days of randomization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in absolute lymphocyte count (ALC) | Baseline through Day 28 | Change in ALC from baseline (Day 1 pre-dose) through Day 28 |
| ICU re-admission rate | Up to Day 90 | Proportion of participants re-admitted to ICU after discharge by Day 90 |
| Secondary infections | Up to Day 90 | Proportion of participants with secondary infections after discharge by Day 90 |
| 90-day all-cause mortality rate | 90 days | Proportion of participants who die from any cause within 90 days of randomization |
| Safety and tolerability | Through Day 30 after last dose | Incidence and severity of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and Grade ≥3 TEAEs graded per NCI CTCAE v6.0 |
Contacts
CONTACTAlex Golway
CONTACTTamra Madenwald
Outcome results
None listed